If people think they are invested in an embryonic stem cell company, they need to think again, because they are not. We are talking about adult donor cells.
Caplan, after publishing his seminal paper in the early 1990s, had called on a name change for mesenchymal stromal cells to medicinal signal cells, and here’s his explanation
https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0051
Here’s another piece from an industry body on the nomenclature, published 2 years later, in 2019:
https://iris.univr.it/bitstream/11562/1033130/1/Viswanathan%20et%20al%20Mesenchymal%20Stem%20vs.%20Stromal%20cells%20ISCT%20Cytotherapy%202019.pdf
(This is probably the thread where this kind of discussion belongs, more so than the NASDAQ trading one - excuse me for re-starting it here.)
Cell Therapy News/Articles, page-18018
-
- There are more pages in this discussion • 374 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |